Shares of Geovax Labs (GOVX) are moving higher after Siga Technologies (SIGA) announced topline results from a preliminary analysis of the PALM 007 study for the treatment of monkeypox virus. The National Institute of Allergy and Infectious Disease reported that the study did not meet its primary endpoint of a statistically significant improvement in time to lesion resolution within 28 days post-randomization for patients in the Democratic Republic of the Congo with monkeypox, who were administered Siga’s tecovirimat. In December 2023, GeoVax amended a previously executed license agreement with the National Institute of Allergy and Infectious Diseases to expand the company’s commercial license to include mpox and smallpox as additional indications. GeoVax shares are up 19% in premarket trading to $3.86 while Siga is down 2% to $11.70.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOVX:
- GeoVax Labs appoints Lambe to Scientific Advisory Board
- GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
- WHO to consider emergency as Mpox resurfaces in Africa, News Central reports
- GeoVax Labs files to sell 2.17M shares of common stock for holders
- GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update